CompletedPhase 2NCT02313610

Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis

Studying Primary pulmonary tuberculosis

Last synced from ClinicalTrials.gov May 18, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Shanghai University of Traditional Chinese Medicine
Principal Investigator: Guang Ji
Shanghai University of Traditional Chinese Medicine
Intervention: Qinbudan(drug)
Enrollment: 253 enrolled
Eligibility: 18-65 years · All sexes
Timeline: 2011 – 2013

Study locations (12)

Hebei provincial chest hospital, Shijiazhuang, Hebei, China
The first affiliated hospital of Xinxiang Medical University, Xinxiang, Henan, China
Wuhan tuberculosis dispensary, Wuhan, Hubei, China
Jiangxi provincial chest hospital, Nanchang, Jiangxi, China
Shenyang chest hospital, Shenyang, Liaoning, China
Uygur Autonomous Region of Xinjiang Chest Hospital, Ürümqi, Xinjiang, China
Beijing chest hospital,Capital medical university, Beijing, China
The first affiliated hospital of chongqing medical university, Chongqing, China
The 85th hospital of chinese people's liberation army, Shanghai, China
Shanghai pulmonary hospital affiliated Tongji University, Shanghai, China
Shenzhen Donghu hospital, Shenzhen, China
Tianjin Haihe hospital, Tianjin, China

Collaborators

Ministry of Science and Technology of the People´s Republic of China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02313610 on ClinicalTrials.gov

Other trials for Primary pulmonary tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Primary pulmonary tuberculosis →

← Back to all trials